259 related articles for article (PubMed ID: 24004182)
21. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
22. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
[TBL] [Abstract][Full Text] [Related]
23. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
[TBL] [Abstract][Full Text] [Related]
24. NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Zhao D; Zarif M; Eladl E; Capo-Chichi JM; Smith AC; Atenafu EG; Tierens A; Minden MD; Schuh A; Chang H
Leuk Res; 2022 Jul; 118():106869. PubMed ID: 35636054
[TBL] [Abstract][Full Text] [Related]
25. The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
Pastore F; Greif PA; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Braess J; Sauerland CM; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Spiekermann K
PLoS One; 2014; 9(10):e109759. PubMed ID: 25299584
[TBL] [Abstract][Full Text] [Related]
26. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
El Hussein S; DiNardo CD; Takahashi K; Khoury JD; Fang H; Furudate K; Lyapichev KA; Garces S; Kanagal-Shamanna R; Ok CY; Patel KP; Routbort MJ; Ravandi F; Medeiros LJ; Wang SA; Loghavi S
Bone Marrow Transplant; 2022 Mar; 57(3):370-376. PubMed ID: 34992253
[TBL] [Abstract][Full Text] [Related]
27. NPM1 gene mutation in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Sofan MA; Elmasry S; Salem DA; Bazid MM
Clin Lab; 2014; 60(11):1813-22. PubMed ID: 25648021
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
Park BG; Chi HS; Park SJ; Min SK; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Acta Haematol; 2012; 127(2):63-71. PubMed ID: 22104247
[TBL] [Abstract][Full Text] [Related]
29. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
30. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression.
Kristensen T; Møller MB; Friis L; Bergmann OJ; Preiss B
Eur J Haematol; 2011 Nov; 87(5):400-8. PubMed ID: 21707751
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.
De Clara E; Gourvest M; Ma H; Vergez F; Tosolini M; Dejean S; Demur C; Delabesse E; Recher C; Touriol C; Martelli MP; Falini B; Brousset P; Bousquet M
Haematologica; 2017 Oct; 102(10):1718-1726. PubMed ID: 28679652
[TBL] [Abstract][Full Text] [Related]
32. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
33. [Coexisting mutations in NPM1-mutated elderly adults with acute myeloid leukemia].
Qin W; Chao HY; Cai XH; Lu XZ; Liu J; Wu P; Chen MY
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3152-3157. PubMed ID: 31694106
[No Abstract] [Full Text] [Related]
34. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
35. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
36. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Minimal Residual Disease in Standard-Risk AML.
Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes A; Grech A; Patel Y; Bhudia N; Farah H; Mason J; Wall K; Akiki S; Griffiths M; Solomon E; McCaughan F; Linch DC; Gale RE; Vyas P; Freeman SD; Russell N; Burnett AK; Grimwade D;
N Engl J Med; 2016 Feb; 374(5):422-33. PubMed ID: 26789727
[TBL] [Abstract][Full Text] [Related]
38. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
39. [Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype].
Liu YR; Lai YY; Chang Y; Ruan GR; Qin YZ; Wang YZ; Zhu HH; Shi HX; Jiang B; Jiang H; Jiang Q; Hao L; Li JL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1385-9. PubMed ID: 24370016
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
